{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:07:39Z","timestamp":1792757259296,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K11652"],"award-info":[{"award-number":["JP24K11652"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24KJ1707"],"award-info":[{"award-number":["JP24KJ1707"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019770","name":"National Institutes of Natural Sciences Exploratory Research Center on Life and Living Systems","doi-asserted-by":"publisher","award":["21\\u2013101"],"award-info":[{"award-number":["21\\u2013101"]}],"id":[{"id":"10.13039\/501100019770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003382","name":"Core Research for Evolutional Science and Technology","doi-asserted-by":"publisher","award":["JPMJCR18S4"],"award-info":[{"award-number":["JPMJCR18S4"]}],"id":[{"id":"10.13039\/501100003382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25gm1810008"],"award-info":[{"award-number":["JP25gm1810008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23am0401002"],"award-info":[{"award-number":["JP23am0401002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18am0301009"],"award-info":[{"award-number":["JP18am0301009"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25gm1610006"],"award-info":[{"award-number":["JP25gm1610006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21am0101124"],"award-info":[{"award-number":["JP21am0101124"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25ama121046"],"award-info":[{"award-number":["JP25ama121046"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25gm0010010"],"award-info":[{"award-number":["JP25gm0010010"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biopha.2025.118336","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T18:01:41Z","timestamp":1752602501000},"page":"118336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting of bowel tissue by fully human antibodies cross-reactive with human and mouse GPA33 antigen"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-7456","authenticated-orcid":false,"given":"Genki","family":"Hichiwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdur","family":"Rafique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Kazuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Ogihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4567-3763","authenticated-orcid":false,"given":"Muhammad Feisal","family":"Jatnika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Shimamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-1167","authenticated-orcid":false,"given":"Narumi","family":"Uno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Satofuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Tomizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4818-4710","authenticated-orcid":false,"given":"Yasuhiro","family":"Kazuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2025.118336_bib1","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.biopha.2025.118336_bib2","first-page":"465","article-title":"Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy","volume":"9","author":"Garinchesa","year":"1996","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2025.118336_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1073\/pnas.94.2.469","article-title":"The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily","volume":"94","author":"Heath","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2025.118336_bib4","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.1994.12.8.1561","article-title":"Phase I\/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer","volume":"12","author":"Welt","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118336_bib5","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1200\/JCO.1996.14.6.1787","article-title":"Phase I\/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer","volume":"14","author":"Welt","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118336_bib6","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1158\/1078-0432.CCR-04-2330","article-title":"Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma","volume":"11","author":"Chong","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118336_bib7","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1007\/s00259-015-3061-2","article-title":"PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer","volume":"42","author":"Zanzonico","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.biopha.2025.118336_bib8","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2967\/jnumed.110.086165","article-title":"(124)I-huA33 antibody PET of colorectal cancer","volume":"52","author":"Carrasquillo","year":"2011","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2025.118336_bib9","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.2967\/jnumed.111.095596","article-title":"124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET","volume":"52","author":"O'Donoghue","year":"2011","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2025.118336_bib10","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1200\/JCO.1990.8.11.1894","article-title":"Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33","volume":"8","author":"Welt","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118336_bib11","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1158\/1078-0432.CCR-04-2329","article-title":"A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake","volume":"11","author":"Scott","year":"2005","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2025.118336_bib12","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.ejca.2012.11.033","article-title":"Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer","volume":"49","author":"Infante","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118336_bib13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s10637-014-0088-3","article-title":"Phase 1\/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer","volume":"32","author":"Bendell","year":"2014","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.biopha.2025.118336_bib14","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1158\/1535-7163.MCT-17-1086","article-title":"Development of MGD007, a gpA33 x CD3-bispecific DART protein for T-cell immunotherapy of metastatic colorectal cancer","volume":"17","author":"Moore","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118336_bib15","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/bjc.1995.516","article-title":"Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy","volume":"72","author":"King","year":"1995","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118336_bib16","doi-asserted-by":"crossref","first-page":"13668","DOI":"10.1074\/jbc.275.18.13668","article-title":"The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies","volume":"275","author":"Rader","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118336_bib17","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.7150\/thno.107209","article-title":"GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancer","volume":"15","author":"Roux","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2025.118336_bib18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41388-024-03200-3","article-title":"GPA33 expression in colorectal cancer can be induced by WNT inhibition and targeted by cellular therapy","volume":"44","author":"B\u00f6rding","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118336_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-021-06427-w","article-title":"Trastuzumab does not bind rat or mouse ErbB2\/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics","volume":"191","author":"Lewis Phillips","year":"2022","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.biopha.2025.118336_bib20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drudis.2008.12.008","article-title":"Translational strategies for development of monoclonal antibodies from discovery to the clinic","volume":"14","author":"Tabrizi","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2025.118336_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214404","article-title":"A new technology for increasing therapeutic protein levels in the brain over extended periods","volume":"14","author":"Nakano","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118336_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.111914","article-title":"Transchromosomic technology for genomically humanized animals","volume":"390","author":"Moriwaki","year":"2020","journal-title":"Exp. Cell Res"},{"key":"10.1016\/j.biopha.2025.118336_bib23","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/s41467-022-29421-2","article-title":"Efficient human-like antibody repertoire and hybridoma production in trans-chromosomic mice carrying megabase-sized human immunoglobulin loci","volume":"13","author":"Satofuka","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118336_bib24","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.immuni.2021.08.025","article-title":"A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site","volume":"54","author":"Onodera","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2025.118336_bib25","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1038\/s41598-023-31263-x","article-title":"Characterization of human anti-EpCAM antibodies for developing an antibody-drug conjugate","volume":"13","author":"Satofuka","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118336_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111258","article-title":"Mice carrying the full-length human immunoglobulin loci produce antigen-specific human antibodies with the lambda light chain","volume":"27","author":"Shimoya","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.biopha.2025.118336_bib27","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.4049\/jimmunol.180.4.2294","article-title":"Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats","volume":"180","author":"Tawara","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2025.118336_bib28","article-title":"inventors. Compound, salt of compound, antibody modification reagent, method for producing modified antibody, and modified antibody","author":"Ito","year":"2023","journal-title":"World Intellect. Prop. Organ."},{"key":"10.1016\/j.biopha.2025.118336_bib29","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/19420862.2015.1125067","article-title":"Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM","volume":"8","author":"Cho","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.biopha.2025.118336_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk1894","article-title":"Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data","volume":"10","author":"Rubahamya","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2025.118336_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115470","article-title":"A precisely humanized FCRN transgenic mouse for preclinical pharmacokinetics studies","volume":"210","author":"Conner","year":"2023","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.biopha.2025.118336_bib32","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/hmg\/dds468","article-title":"Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans","volume":"22","author":"Kazuki","year":"2013","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.biopha.2025.118336_bib33","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1073\/pnas.1808255116","article-title":"Humanized UGT2 and CYP3A transchromosomic rats for improved prediction of human drug metabolism","volume":"116","author":"Kazuki","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118336_bib34","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1101\/gr.6.9.846","article-title":"Comparative analysis of 1196 orthologous mouse and human full-length mRNA and protein sequences","volume":"6","author":"Maka\u0142owski","year":"1996","journal-title":"Genome Res"},{"key":"10.1016\/j.biopha.2025.118336_bib35","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1714371","article-title":"A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis","volume":"12","author":"Murer","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.biopha.2025.118336_bib36","doi-asserted-by":"crossref","first-page":"G500","DOI":"10.1152\/ajpgi.2000.279.3.G500","article-title":"Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells","volume":"279","author":"Johnstone","year":"2000","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.biopha.2025.118336_bib37","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1158\/1535-7163.MCT-18-0026","article-title":"Development of a tetravalent anti-GPA33\/anti-CD3 bispecific antibody for colorectal cancers","volume":"17","author":"Wu","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118336_bib38","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1111\/febs.13262","article-title":"Preparation of an engineered safer immunotoxin against colon carcinoma based on the ribotoxin hirsutellin A","volume":"282","author":"Tom\u00e9-Amat","year":"2015","journal-title":"FEBS J."},{"key":"10.1016\/j.biopha.2025.118336_bib39","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3390\/cancers15041114","article-title":"A new optimized version of a colorectal cancer-targeted immunotoxin based on a non-immunogenic variant of the ribotoxin \u03b1-sarcin","volume":"15","author":"Narbona","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2025.118336_bib40","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1021\/acs.molpharmaceut.0c00210","article-title":"Selective photokilling of colorectal tumors by near-infrared photoimmunotherapy with a GPA33-targeted single-chain antibody variable fragment conjugate","volume":"17","author":"Wei","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.118336_bib41","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2967\/jnumed.124.267685","article-title":"Theranostic GPA33-pretargeted radioimmunotherapy of human colorectal carcinoma with a bivalent 177Lu-labeled radiohapten","volume":"65","author":"Vaughn","year":"2024","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.biopha.2025.118336_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","author":"Hwang","year":"2005","journal-title":"Methods"},{"key":"10.1016\/j.biopha.2025.118336_bib43","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.biopha.2025.118336_bib44","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/s41598-022-06814-3","article-title":"Panel of human cell lines with human\/mouse artificial chromosomes","volume":"12","author":"Uno","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118336_bib45","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1038\/s41467-023-41132-w","article-title":"Systematic transcriptional analysis of human cell lines for gene expression landscape and tumor representation","volume":"14","author":"Jin","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118336_bib46","article-title":"Comparative analysis of trans-chromosomic rodent models reveals improved somatic hypermutation and class-switch recombination in rats","author":"Satofuka","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2025.118336_bib47","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000049195","article-title":"Nomenclature of the human immunoglobulin kappa (IGK) genes","volume":"18","author":"Lefranc","year":"2001","journal-title":"Exp. Clin. Immunogenet."},{"key":"10.1016\/j.biopha.2025.118336_bib48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000049189","article-title":"Nomenclature of the human immunoglobulin heavy (IGH) genes","volume":"18","author":"Lefranc","year":"2001","journal-title":"Exp. Clin. Immunogenet."},{"key":"10.1016\/j.biopha.2025.118336_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167860","article-title":"An anti-human Lutheran glycoprotein phage antibody inhibits cell migration on laminin-511: Epitope mapping of the antibody","volume":"12","author":"Enomoto-Okawa","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118336_bib50","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1089\/mab.2013.0068","article-title":"Selection and characterization of human serum albumin-specific porcine scFv antibodies using a phage display library","volume":"33","author":"Muraoka","year":"2014","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"10.1016\/j.biopha.2025.118336_bib51","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.3390\/ijms241310804","article-title":"A novel strategy for screening tumor-specific variable domain of heavy-chain antibodies","volume":"24","author":"Rafique","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118336_bib52","doi-asserted-by":"crossref","unstructured":"Clackson T., Lowman H., editors. Phage Display: A Practical Approach. Oxford: Oxford University Press; 2004.","DOI":"10.1093\/oso\/9780199638734.001.0001"},{"key":"10.1016\/j.biopha.2025.118336_bib53","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jb\/mvy005","article-title":"Development of sugar chain-binding single-chain variable fragment antibody to adult T-cell leukemia cells using glyco-nanotechnology and phage display method","volume":"163","author":"Muchima","year":"2018","journal-title":"J. Biochem"},{"key":"10.1016\/j.biopha.2025.118336_bib54","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jb\/mvi148","article-title":"Human anti-human IL-18 antibody recognizing the IL-18-binding site 3 with IL-18 signaling blocking activity","volume":"138","author":"Hamasaki","year":"2005","journal-title":"J. Biochem"},{"key":"10.1016\/j.biopha.2025.118336_bib55","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.4049\/jimmunol.147.5.1709","article-title":"Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites","volume":"147","author":"Kabat","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2025.118336_bib56","series-title":"In: Paul, S, editor. Antibody Engineering Protocols","first-page":"1","article-title":"SEQHUNT: A program to screen aligned nucleotide and amino acid sequences","author":"Johnson","year":"2003"},{"key":"10.1016\/j.biopha.2025.118336_bib57","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1093\/bioinformatics\/btq461","article-title":"Search and clustering orders of magnitude faster than BLAST","volume":"26","author":"Edgar","year":"2010","journal-title":"Bioinformatics"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500530X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500530X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T12:04:43Z","timestamp":1754654683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222500530X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":57,"alternative-id":["S075333222500530X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118336","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting of bowel tissue by fully human antibodies cross-reactive with human and mouse GPA33 antigen","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118336"}}